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The G12 subfamily of heterotrimeric G-proteins consists of two
members, G12 and G13. Gene-targeting studies have revealed a role
for G13 in blood vessel development. Mice lacking the  subunit of
G13 die around embryonic day 10 as the result of an angiogenic
defect. On the other hand, the physiological role of G12 is still
unclear. To address this issue, we generated G12-deficient mice. In
contrast to the G13-deficient mice, G12-deficient mice are viable,
fertile, and do not show apparent abnormalities. However, G12
does not seem to be entirely redundant, because in the offspring
generated from G12 G13 intercrosses, at least one intact G12
allele is required for the survival of animals with only one G13
allele. In addition, G12 and G13 showed a difference in mediating
cell migratory response to lysophosphatidic acid in embryonic
fibroblast cells. Furthermore, mice lacking both G12 and Gq die
in utero at about embryonic day 13. These data indicate that the
G12-mediated signaling pathway functionally interacts not only
with the G13- but also with the Gq/11-mediated signaling
systems.
Heterotrimeric G proteins transduce a variety of signalsgenerated by the interaction of hormones, growth factors,
neurotransmitters, odorants, or photons, with cell surface re-
ceptors. On the basis of sequence similarities of the  subunits,
G proteins were grouped into four subfamilies: Gs, Gi,o, Gq, and
G12 (1). Members of the G12 subfamily, G12 and G13, are
ubiquitously expressed and share 67% amino acid identity (2).
Receptors that respond to a variety of ligands, such as those for
thrombin, thromboxane A2, lysophosphatidic acid (LPA), sphin-
gosine 1-phosphate, thyroid-stimulating hormone, bradykinin,
endothelin, neurokinin A, and angiotensin AT1A, have been
shown to couple to G12 andor G13 (3–11). Both the activated
forms of G12 and G13, G12Q229L and G13Q229L, were
found to cause transformation of fibroblasts (12–14), to activate
the JNK pathway (15, 16), to activate the serum response
element (17, 18), and to regulate different isoforms of NaH
exchangers (19–22). Activated G12 and G13 lead to stress fiber
formationfocal adhesion assembly in Swiss 3T3 cells (23) and to
neurite retraction in PC-12 cells (24). In addition, G12 and G13
have been shown to activate phospholipase-D (25, 26) as well as
the transcription of cyclooxygenase-2 (27) and Egr-1, a primary
response gene implicated in cell proliferation (28). The small
GTPases Ras, Rac, CDC42, and especially RhoA seem to play
a critical role in G12 and G13 signaling processes. Regulatory
molecules such as RhoA-specific guanine nucleotide exchange
factors p115RhoGEF (GEF, guanine nucleotide exchange fac-
tor) and PDZ-RhoGEF, and the GTPase-activating protein
RasGAP1 were found to mediate some of these effects by a
direct interaction with G12 and G13 (29–31). Furthermore, the
G12 family proteins have been shown to activate tyrosine kinases,
including epidermal growth factor receptor tyrosine kinase (32),
TecBmx kinases (33), focal adhesion kinase (FAK) (34), and
Pyk-2 (35).
In many experiments, particularly transfection experiments,
G12 and G13 showed mostly overlapping functions when
dominant active mutant forms were used. However, G12 and
G13 seem to differ in their ability to couple to different ligands
as well as to activate tyrosine kinase. For example, LPA appar-
ently activates stress fiber formation through a G13-mediated
process involving epidermal growth factor receptor (EGFR)
transactivation, whereas G12 seems to mediate the stress fiber
formation on thrombin stimulation, without the participation of
EGFR (24, 32). It was also demonstrated that G12 and G13
recruit different signaling pathways to activate NaH ex-
changers (19). In addition, G12 and G13 seem to signal to
RhoA through different pathways. The RhoA guanine–
nucleotide exchange factor p115RhoGEF bound to and acted as
a GTPase-activating protein for both G12 and G13; however,
its activity as a GEF was activated only by G13, but not G12
(36). Furthermore, G12 appears to have a much stronger ability
to induce transformation compared with G13, whereas G13
leads to more severe apoptosis in COS7 cells (12, 13, 37–39).
These data suggest that G12 and G13 have similar activities
with respect to some functions but are nevertheless readily
distinguishable with respect to other functions.
In recent years, gene targeting experiments in mice have been
used to learn more about the physiological role of G proteins.
The absence of G13 resulted in impaired angiogenesis and
intrauterine death at day 10. We have now generated mice
deficient for G12. In contrast to the G13-deficient animals, the
G12-knockout mice are alive and show no apparent phenotype.
However, crossbreeding with mice carrying a mutation in the
G13 or Gq gene suggests that G12 has a role in mouse
embryogenesis, and that it functionally interacts with signaling
pathways using both G13 and Gq.
Materials and Methods
Generation of G12-Deficient Mice. A genomic clone containing
exons 3 and 4 of the G12 gene was isolated from 129Sv mouse
 phage library (Stratagene) (40). To generate the targeting
construct, a 701-bp XhoI–HpaI fragment of exon 4 encoding the
C-terminal 127 amino acids was replaced by the Pgk::Neo gene
in the reverse orientation. The short arm of the targeting
construct consisted of a 2-kb HpaI–XhoI fragment, and the long
arm consisted of a 4.5-kb AflII–HpaI fragment. The targeting
construct was introduced into the CJ7 mouse embryonic stem
(ES) cell line by electroporation, and the resulting G418-
resistant clones were screened with a 0.9-kb BamHI–HpaI probe
located upstream of the short arm for correct integration into the
genome by Southern blot analysis. ES cells with the null mutation
in one G12 allele were injected into C57BL6 blastocysts, and
chimeras were bred with C57BL6 and 129Sv mice to generate
heterozygous mice. Further intercrosses of the heterozygous
mice produced homozygous G12-deficient mice.
Western Analysis. Proteins for Western analysis were prepared
from mouse brains (41). Samples were separated by SDSPAGE
and blotted onto nitrocellulose membranes BA85 (Schleicher &
Abbreviations: LPA, lysophosphatidic acid; MEF, mouse embryonic fibroblasts; En, embry-
onic day n; ES, embryonic stem; GEF, guanine nucleotide exchange factor.
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Schu¨ll). G12 was detected by the N-terminal-specific polyclonal
antibody S-20 (1:300, Santa Cruz Biotechnology) or by the
C-terminal antiserum AS233 (1:300).
Immunohistochemistry Analysis. Embryos were isolated from uteri
at embryonic days (E)8.25 and 9.5, fixed for 24 h in 4%
paraformaldehyde, then transferred to methanol via consecutive
steps of increasing methanol concentrations and stored at
20°C. Whole-mount immunohistochemical staining of mouse
embryos with antiplatelet–endothelial cell adhesion molecule
(PECAM)-1 monoclonal antibodies was performed as described
(42). Briefly, E9.5 embryos were blocked for 2 h at reverse
transcription in PBS2% nonfat dry milk0.2% Triton X-100 and
incubated with rat anti-mouse-PECAM-1 monoclonal antibody,
cl. 13.3 (0.5 mgml, 1:300, PharMingen) followed by affinity
purified goat anti-rat alkaline phosphatase-conjugated IgG (0.3
mgml, 1:200, The Jackson Laboratory). The embryos were then
washed with alkaline phosphatase buffer (0.1 M TrisHCl, pH
9.50.1 M NaCl50 mM MgCl20.1% Tween 20) including 2 mM
levamisole and stained in the same buffer with 350 gml of
nitro-blue tetrazolium and 175 gml of 5-bromo-4-chloro-3-
indoyl phosphate.
Mouse Embryonic Fibroblast (MEF) Cells and Retroviral Transduction.
MEF cells were isolated from E8.0 G12G13 embryos
or E9.5 G13 embryos, as described (43). Cells were main-
tained and passaged through crisis in DMEM (GIBCOBRL)
supplemented with 10% FBS and 180 g (active component)ml
G418. The retroviral gene delivery system was a generous gift
from Carlos Lois (California Institute of Technology). Mouse
G12 and G13 cDNA was cloned into pBabe-puro retroviral
vector. To produce retrovirus, BOSC packaging cells were
transfected with retroviral constructs as described (44). Virus
was collected 48 h later and centrifuged for 5 min at 1,500  g
to remove cells. Supernatant was aliquoted and frozen at80°C.
MEF cells grown in 6-cm plates to about 60% confluent were
infected with 4 ml of the viral supernatant for 5 h, and permanent
G12 or G13 lines were generated by selection in 2 gml of
puromycin 72 h post-infection.
Cell Migration Assays. Cell migration assays were performed by
using Transwell migration chambers (24 wells with pore size 8
m; Costar). MEF cells were trypsinized to obtain single-cell
suspension and washed twice in migration medium (DMEM
containing 0.5% fatty acid-free BSA). Cells were then resus-
pended in this medium at 1  106 cellsml, and 100 l of this
suspension was placed in the upper compartment of the Trans-
well chamber. Six hundred microliters of migration media or
migration media containing 5 M LPA was placed in the lower
chamber. The chambers were incubated for 4 h at 37°C in a
humidified incubator with 5% CO2 to allow cell migration. After
the incubation period, the filter was removed, and the upper side
of the filters was wiped gently with a cotton applicator to remove
nonmigrated cells. The filters were fixed and stained with a
Giemsa solution (Diff-Quick, Dade Behring AG). Migration was
quantitated by counting cells that had migrated to the lower
surface of the filter. Five random fields in each filter were
counted. Each experiment was performed in triplicate, and
migration was documented as the average number SD of total
cells counted per field. Final results were expressed as the fold
increase over the migration of noninfected cells measured at the
same time. Experiments were repeated at least three times.
Background cell migration (0.5% fatty acid free BSA only) was
less than 5% of stimulated values.
Results
G12 Gene-Targeted Animals Develop Normally and Show No Appar-
ent Morphological or Behavioral Abnormalities. G12-deficient mice
were generated by targeted disruption of the G12 gene in ES
cells. The mutation was generated by replacing an XhoI–HpaI
fragment of exon 4 with the Neo gene through homologous
recombination, which led to the removal of approximately
one-third of the protein-coding sequence (Fig. 1A). ES cells
carrying the deleted gene were identified by Southern analysis,
and chimeric mice were obtained by injecting the 129Sv-derived
heterozygous ES cells into C57BL6 blastocysts. Germ-line-
transmitting chimeric male mice were crossed with females of
both 129Sv and C57BL6 backgrounds. More than 350 mice
from G12 intercrosses were analyzed, and the distribution of
genotypes was Mendelian (Table 1), suggesting that all of the
possible genotypes showed normal levels of survival. Both
heterozygous and homozygous G12 mutant mice were fertile
and did not show apparent morphological or behavioral
abnormalities.
To confirm the absence of G12 expression in mutant mice, we
carried out detailed analysis at both mRNA and protein levels.
Reverse transcription–PCR and Northern analysis confirmed
the presence of the shortened G12 gene transcript (data not
shown). At the protein level, antibodies directed against both the
N and the C termini of G12 protein showed the absence of
reactive protein (Fig. 1B). The lower areas of the Western blot
Fig. 1. Targeted inactivation of the murine G12 gene. (A) Genomic structure
of murine G12 gene (WT), targeting construct (TC), and replaced mutant
allele (Mut.), as described in Materials and Methods. (B) Western analysis of
G12 mice. Cholate extracts from mouse brain were used for detection by
Western analysis. An approximately 45-kDa band representing G12 was seen
in wild-type tissue with antibodies against the N (N-20, Santa Cruz Biotech-
nology) and C termini (AS 233). Expression of G13 and Gq was also examined
in both wild-type and G12 mutant mice.
Table 1. Offspring of G12 intercrosses
G12 129Sv C57BL6J
 16 (22.5%) 74 (27%)
 44 (62%) 147 (53%)
 11 (15.5%) 57 (20%)
Total 71 278
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were also examined and no indication of the presence of a
truncated form was observed. Even in the unlikely event that a
short form were to be produced, it would be likely to be unstable
and to not contain the folded portion of the protein required for
the formation of a functional guanine nucleotide-binding pocket.
We conclude that these mutant mice are devoid of functional
G12 protein.
G12 Interacts with G13 During Mouse Embryonic Development.
G12 is coexpressed with the other member of the G12 family
protein G13 in all tissues tested so far and has been shown in
many cases to have overlapping function with G13. G13
deficiency is characterized by a severe angiogenic defect leading
to embryonic death at E10 (42). The lack of phenotype in G12
gene-targeted mice could result from the compensation for G12
activity by other G proteins, specifically G13. To examine this
possibility, we first compared brain extracts from wild-type and
G12-deficient mice for expression levels of G13 and Gq by
using specific antisera and semiquantitative immunoblot analysis
(Fig. 1B). No significant change in expression of these  subunits
was observed. To further test their genetic interactions,
G12 and G13 mice were crossed to produce
G12G13 heterozygotes, which are viable and fertile. Dou-
ble heterozygotes [G12();G13()] were then intercrossed to
generate offspring with different combinations of G12 and
G13 genes (Table 2). At E8.25 (about the eight-somite stage;
Fig. 2A), G12G13 embryos seem to be arrested.
G12G13 embryos have about two to four somites. Both
types of embryos show clear developmental retardation. Em-
bryos with all other genotypes are indistinguishable from their
wild-type littermates at this stage. At E9.5 (Fig. 2B), almost all
G12G13embryos are either resorbed or show severe
necrosis. Most of the G12G13 embryos show severe
signs of degeneration and are in the process of being resorbed.
Consistent with our previous report (42), at this stage,
G12G13 embryos are obtained alive with signs of the
development of degenerative vascular structure. These embryos
contain 12–14 pairs of somites and are arrested in the turning
process. Embryos with genotypes of G12G13 and
G12G13 are phenotypically the same as their wild-
type littermates. G12G13 embryos are never found at
E10.5 (Table 2). The fact that in the absence of a G12 allele, one
G13 allele is not sufficient for survival suggests that there is
some functional interaction between these two genes. Interest-
ingly, at E9.5, most G12G13 embryos show slightly
retarded phenotypes (Fig. 2B). We have occasionally found
G12G13 embryos with phenotypes indistinguishable
from wild-type as well as G13 embryos (picture not
shown), suggesting background genes may modify the G12
G13 signaling pathway. The functions of G12 and G13 appear
to interact as suggested by the fact that embryos lacking both
G12 and G13 die about 1 day earlier than G12G13
mice (Fig. 2 A, Table 2). Taken together, these data indicate that
the functions of G12 and G13 are partially overlapping during
embryonic development. Nonetheless, in the presence of a full
complement of wild-type G13 alleles, the animals can develop
even if both G12 alleles are disrupted.
G12 and G13 Differ in Their Ability to Mediate LPA-Stimulated Cell
Migration. We previously showed that G13 mediates thrombin-
stimulated cell migration using primary MEFs derived from
wild-type and G13 embryos (42). To reduce the large
variations observed in these experiments that could be due to
different genetic backgrounds, we decided to examine in more
detail the migratory effects of G12 and G13 in stable cell lines.
G13 and G12G13 MEFs were prepared and
passaged through crisis as described in Materials and Methods.
Retrovirus-carrying G12, G13, and green fluorescent protein
(GFP) were used to infect the cells, and stable lines expressing
Table 2. Offspring of G12G13 intercrosses
G12 G13 E8.25 E8.5 E9.5 E10.5 P30 Predicted
  4 2 4 1 18 6.25%
  14 11 28 4 45 12.5%
  4 2 15* 0 0 6.25%
  4 8 16 2 44 12.5%
  18 29 63 8 44 25.0%
  9 7 25* 0 0 12.5%
  4 4 10 1 24 6.25%
  10 15 27* 0 0 12.5%
  5 6* 0 0 0 6.25%
Total 72 85 188 16 172
P30, postnatal day 30.
*Signs of resorption observed.
Fig. 2. Embryos from offspring of G12G13 intercrosses. (A) Embryos
taken at E8.25. (B) Whole-mount staining of E9.5 embryos with antiplatelet–
endothelial cell adhesion molecule-1 antibody (PharMingen).
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G13, G12, and GFP were established by selection in puromycin.
Expression of G13 and G12 was examined by Western analysis
or reverse transcription–PCR (data not shown). We confirmed
the role of G13 in mediating thrombin-stimulated cell migration
in G13 cells (data not shown). In addition, we observed a
clear role of G13 in mediating LPA-stimulated cell migration
(Fig. 3) [the trend was observed before, although not statistically
significant (42)]. Furthermore, in G13, G12, and GFP-
expressing G12G13 cells, although G13 was shown
to mediate LPA-stimulated cell migration, G12 expression did
not seem to affect the migratory ability of the cells (Fig. 3). These
results were observed in two different lines of G13 and
G12G13 MEFs. They clearly demonstrated a differ-
ent role for G12 and G13 in mediating LPA-stimulated cell
migration.
G12 Interacts with Gq During Mouse Embryonic Development.
Further evidence for a function for the G12 gene product comes
from crosses of G12- with Gq-deficient animals. Consistent
with our previous report (45), newborn Gq-deficient mice
occasionally suffer from overt intraabdominal bleeding, which
can lead to perinatal death, and GqG12 and
GqG12 mice have a lower survival rate than expected
at postnatal day 30 (Table 3). In addition, the Gq and G12
doubly deficient animals appear to be normal up to E12.5 but
show clear signs of retardation and beginning resorption at E13.5
(Fig. 4). In contrast, most Gq embryos and almost all
G12 embryos survive. At E12.5, both wild-type and
GqG12 embryos seem to have normally developed
heads, eyes, hearts, and vascular systems. Their hand- and
footplates are paddle-shaped. At E13.5, in the front of the facial
region of the wild-type embryo, mouth and nose are protruded.
The distal borders of the hand- and footplates of the limbs are
now indented, and the definitive location and width of the digits
are clearly seen. However, for GqG12 embryos, the
hand- and footplates are still paddle-shaped. Their development
seems to stop around E12.5, and embryos show clear signs of
degeneration at E13.5. These results suggest an overlapping
function of G12 with Gq that is required for development and
is manifested at about E12.5. Although we still do not know the
details of their function, we have observed that, whereas G12
alone is dispensable, G12 clearly interacts with other G-protein-
mediated pathways, as demonstrated in doubly deficient animals.
Discussion
In this study, we have generated mice deficient for G12. The
G12-deficient mice are normal and show no obvious abnormal-
ities regarding growth, rudimentary behavior, development of
immune system (normal T and B cell development), or fertility.
The effects of removing the G12 gene in mice are in sharp
contrast to the outcome of its close relative, G13. G13 defi-
ciency in mice results in embryonic lethality at E10 due to
impaired angiogenesis in both yolk sac and embryo proper with
enlarged and disorganized blood vessels in the head mesen-
chyme (42). The generation of mice deficient for both G12 and
G13, however, revealed that G12 has a distinct biological
function in mouse embryonic development. Embryos with G12
and G13 double deficiency die between E8 and E8.5. Embryos
carrying only one G12 allele (G12G13) survive a little
Fig. 3. LPA-induced cell migration. GFP, G12, and G13 expressing G13
and G12G13 cell lines were established by using the retroviral
expression system as described in Materials and Methods. Migration experi-
ments were performed in triplicate by using 24-well Transwell migration
chambers, and migrated cells were quantitated in five random fields and
expressed as a percentage of the control cells () that are always run at the
same time. Two different G13 lines and two different G12G13
lines were examined and showed similar results in at least two independent
experiments.
Table 3. Offspring of GqG12 intercrosses
Gq G12 E11.5 E13.5 P30 Predicted
  1 1 19 6.25%
  4 3 19 12.5%
  10 1 16 6.25%
  0 3 23 12.5%
  11 8 47 25.0%
  13 0 42 12.5%
  1 1 4 6.25%
  5 2 6 12.5%
  10 3* 0 6.25%
Total 55 22 176
P30, postnatal day 30.
*Signs of resorption observed.
Fig. 4. Embryos from offspring of GqG12 intercrosses. (A) Embryos
taken at E12.5. (B) Embryos taken at E13.5.
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longer and die around E9.0. The presence of a single allele of
G13 in combination with a single G12 allele is sufficient to
provide survival. However, in the absence of a G12 allele, one
G13 allele is not sufficient for survival (Table 2). These results
suggest that G12 has an overlapping as well as distinct function
with G13 in early mouse development.
G12 and G13 doubly deficient embryos at E8.25 have a
poorly developed headfold, no somites, and unclosed and some-
times kinked neural tubes (Fig. 2 A). The allantois is short and
thick and not fused to the chorion. All these features resemble
closely the phenotypes observed in mice deficient for genes
involved in cell migration and cell adhesion such as fibronectin,
p125FAK, or vinculin (46–49), and are consistent with evidence
for a pivotal role for G12 and G13 in mediating signals leading
to cytoskeleton rearrangement and extracellular matrix adhe-
sion. For example, LPA that causes rearrangements of the actin
cytoskeleton via the G12 subfamily induces enhanced binding of
fibronectin to cells (50). Moreover, leukocyte adhesion to en-
dothelial cells via certain integrins is Rho-dependent (51) and
might also involve G12 or G13. Finally, active forms of G12
and G13 lead to phosphorylation of p125FAK and associated
proteins like paxillin and p130Cas and directly link them to cell
adhesion (34). Recently, G12 and G13 were also shown to
interact directly with cadherin and induce the release of -
catenin on activation, providing more evidence for the involve-
ment of G12 and G13 in cell adhesion (52). The phenotypes
observed in G12 and G13 doubly deficient embryos suggest an
overlapping function of G12 with G13 during early embryo-
genesis. A gene-dosage effect was also observed, because at least
one intact allele of both G12 and G13 is required to overcome
the early developmental block. In contrast to the clear overlap-
ping functions of G12 and G13 during mouse development,
G12 and G13 displayed a difference in their ability to mediate
receptor-dependent chemokinetic effects. Although expression
of G13 in G13-deficient cells leads to increased migratory
response, expression of G12 does not seem to have an effect.
Small G proteins, including RhoA, Rac, and Cdc42, have been
implicated in the signaling processes involved in cell migration.
Although both G12 and G13 have been shown to signal through
small G proteins, especially RhoA, differences exist in the ways
the signals are transmitted. For example, although both G12 and
G13 use p115RhoGEF as GAP only activated G13, but not
activated G12, stimulates its GEF activity (36). Thus, in our
embryonic fibroblast system, G12 does not mediate the che-
mokinetic response to LPA, whereas G13 does.
G12G13-mediated signaling pathways have also been
shown to functionally interact with GqG11-mediated signal-
ing processes, most likely in a synergistic manner. For example,
in platelets, thromboxane-A2 (TXA2) receptor-induced Gq
activation leads to phospholipase C-Ca2calmodulin-
dependent myosin light chain kinase activation, whereas TXA2
receptor-induced G12G13 activation results in activation of
RhoRho-kinase, which further phosphorylates and inhibits
myosin phosphatase. Thus, Gq and G12G13 synergistically
increase myosin light chain phosphorylation in activated plate-
lets (42, 53, 54) and possibly in a variety of other cells. Previous
work in our lab with Gq and G11 double knockout mice
showed that the relationship between Gq and G11 in mouse
development is similar to that of G12 and G13. At least one
intact copy of either Gq or G11 is required to bring embryos
to term (55). We were interested in examining whether G12 also
interacts with the Gq signaling pathway. Double heterozygous
breeding shows that Gq and G12 doubly deficient animals die
in utero at about E13 (Table 3), whereas most Gq embryos
and almost all G12 embryos survive. These results suggest
an overlapping function of G12 with Gq at a different stage of
embryogenesis than the functional overlap found with G13.
Interestingly, the gene-dosage effect between G12 and Gq
differs from the gene-dosage effect between G12 and G13 (at
least one intact allele of both G12 and G13 is necessary for
extrauterine life), whereas at least one intact copy of either Gq
or G12 is required. Although the physiological role that G12
plays in these processes is still not clear, our results demonstrate
functional overlap between G12 and G13 or Gq during
different stages of embryogenesis. Although we have not iden-
tified the processes in which each of these genes plays a dominant
role, we can clearly see where their functions overlap. Extensive
studies with isolated cells deficient in different G proteins will be
necessary to analyze the nature of these signaling networks.
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